NO150361C - Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater - Google Patents

Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater

Info

Publication number
NO150361C
NO150361C NO781786A NO781786A NO150361C NO 150361 C NO150361 C NO 150361C NO 781786 A NO781786 A NO 781786A NO 781786 A NO781786 A NO 781786A NO 150361 C NO150361 C NO 150361C
Authority
NO
Norway
Prior art keywords
tetrazol
pyrido
pyrimidin
derivatives
preparation
Prior art date
Application number
NO781786A
Other languages
English (en)
Norwegian (no)
Other versions
NO150361B (no
NO781786L (no
Inventor
Peter Frederick Juby
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NO781786L publication Critical patent/NO781786L/no
Publication of NO150361B publication Critical patent/NO150361B/no
Publication of NO150361C publication Critical patent/NO150361C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO781786A 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater NO150361C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (3)

Publication Number Publication Date
NO781786L NO781786L (no) 1978-11-28
NO150361B NO150361B (no) 1984-06-25
NO150361C true NO150361C (no) 1984-10-03

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO781786A NO150361C (no) 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater

Country Status (26)

Country Link
US (1) US4122274A (fr)
JP (1) JPS6050197B2 (fr)
AT (1) AT365187B (fr)
AU (1) AU521211B2 (fr)
BE (1) BE867295A (fr)
CA (1) CA1098520A (fr)
CH (1) CH642656A5 (fr)
CY (1) CY1218A (fr)
DE (1) DE2822544A1 (fr)
DK (1) DK160279C (fr)
FI (1) FI64594C (fr)
FR (1) FR2401159A1 (fr)
GB (1) GB1596476A (fr)
GR (1) GR71887B (fr)
HK (1) HK25884A (fr)
IE (1) IE46849B1 (fr)
IT (1) IT1105040B (fr)
KE (1) KE3357A (fr)
LU (1) LU79694A1 (fr)
MY (1) MY8500305A (fr)
NL (1) NL190702C (fr)
NO (1) NO150361C (fr)
SE (1) SE437830B (fr)
SG (1) SG73383G (fr)
YU (2) YU42163B (fr)
ZA (1) ZA782816B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
DK169580B1 (da) * 1985-09-25 1994-12-12 Shionogi & Co 9-(substitueret thio)-4H-pyrido[1,2-a]pyrimidin-4-on-derivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende sådanne derivater
JPS63183581A (ja) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd ピリド〔１，２−ａ〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬
JPS62242682A (ja) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd 新規なピリド［１，２―ａ］ピリミジン誘導体及びその製造法
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
DE3882042T2 (de) * 1987-12-25 1993-09-30 Santen Pharma Co Ltd Antiallergische augentropfen.
CA2010336C (fr) * 1989-02-27 1996-11-19 Atsunori Sano Procede de production d'un derive de pyrido [1,2-a] pyrimidine
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
CA2138957A1 (fr) 1992-07-30 1994-02-17 Shigeki Omura Remede contre les maladies intestinales inflammatoires
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (ja) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd ９−メチル−３−（１Ｈ−テトラゾール−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンの水性製剤
WO2002072580A1 (fr) * 2001-02-26 2002-09-19 Mitsubishi Pharma Corporation Preventifs et/ou remedes contres des maladies renales et l'insuffisance renale
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
GB0316546D0 (en) * 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
HRP20120923T1 (hr) * 2006-12-18 2012-12-31 Cardoz Ab Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja
CA2673214A1 (fr) * 2006-12-20 2008-06-26 Cardoz Ab Nouvelle combinaison destinee a etre utilisee dans le traitement de troubles inflammatoires
WO2009007679A2 (fr) * 2007-07-11 2009-01-15 Cardoz Ab Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
WO2009007673A2 (fr) * 2007-07-11 2009-01-15 Cardoz Ab Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
WO2009007675A2 (fr) * 2007-07-11 2009-01-15 Cardoz Ab Nouvelle association pour une utilisation dans le traitement de troubles inflammatoires
CA2720547A1 (fr) * 2008-04-07 2009-10-15 Cardoz Ab Nouvelle combinaison pour une utilisation dans le traitement de troubles inflammatoires
EP2443120B1 (fr) * 2009-06-16 2016-11-02 RSPR Pharma AB Forme cristalline de pémirolast
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
KR102341596B1 (ko) 2012-02-10 2021-12-21 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
CA2865957C (fr) 2012-03-01 2020-02-11 F. Hoffmann-La Roche Ag Composes pour le traitement de l'amyotrophie spinale
EP2828247B1 (fr) 2012-03-23 2019-01-16 PTC Therapeutics, Inc. Dérivés de la 4h-chromèn-4-one pour le traitement de l'amyotrophie spinale
US10195202B2 (en) 2013-12-19 2019-02-05 Ptc Therapeutics, Inc. Methods for modulating the amount of RNA transcripts
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (fr) 2014-12-22 2016-06-30 Rspr Pharma Ab Nouvelle association pémirolast et montélukast
CN107635999B (zh) * 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
EP4249472A3 (fr) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Procédés de modulation de l'épissage de l'arn
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
MX391850B (es) 2015-12-10 2025-03-19 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
WO2018098446A1 (fr) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Procédés de modulation de l'épissage de l'arn
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
EP3645121B8 (fr) 2017-06-28 2025-06-18 PTC Therapeutics, Inc. Méthodes de traitement de la maladie de huntington
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
WO2020005882A1 (fr) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Composés hétéroaryles pour le traitement de la maladie de huntington
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
KR20220022114A (ko) 2019-05-13 2022-02-24 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
AT296996B (de) * 1966-11-02 1972-03-10 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Homopyrimidazolderivaten und deren Säureadditionssalzen und quaternären Ammoniumsalzen
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
CH642656A5 (de) 1984-04-30
DK160279B (da) 1991-02-18
AU521211B2 (en) 1982-03-25
JPS5436294A (en) 1979-03-16
BE867295A (fr) 1978-11-20
DK228878A (da) 1978-11-26
AT365187B (de) 1981-12-28
NO150361B (no) 1984-06-25
KE3357A (en) 1984-02-03
IE46849B1 (en) 1983-10-05
MY8500305A (en) 1985-12-31
FR2401159B1 (fr) 1983-05-20
DE2822544C2 (fr) 1988-10-27
CY1218A (en) 1984-04-06
NL7805534A (nl) 1978-11-28
CA1098520A (fr) 1981-03-31
DK160279C (da) 1991-07-22
FR2401159A1 (fr) 1979-03-23
YU44212B (en) 1990-04-30
SE437830B (sv) 1985-03-18
FI781614A7 (fi) 1978-11-26
IT1105040B (it) 1985-10-28
YU233082A (en) 1988-08-31
HK25884A (en) 1984-03-30
ZA782816B (en) 1979-05-30
NL190702C (nl) 1994-07-01
GR71887B (fr) 1983-08-04
GB1596476A (en) 1981-08-26
IE781036L (en) 1978-11-25
LU79694A1 (fr) 1979-02-02
US4122274A (en) 1978-10-24
JPS6050197B2 (ja) 1985-11-07
AU3631978A (en) 1979-11-29
YU123678A (en) 1983-02-28
SE7805954L (sv) 1978-11-26
ATA373278A (de) 1981-05-15
DE2822544A1 (de) 1978-12-07
SG73383G (en) 1984-08-03
YU42163B (en) 1988-06-30
NO781786L (no) 1978-11-28
FI64594B (fi) 1983-08-31
NL190702B (nl) 1994-02-01
FI64594C (fi) 1983-12-12
IT7849523A0 (it) 1978-05-24

Similar Documents

Publication Publication Date Title
NO150361C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
NO155774C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazo-diazepin-derivater.
NO145657C (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive alkenderivater.
NO148148C (no) Fremgangsmaate til fremstilling av terapeutisk aktive 4-hydroksy-2-pyrrolidinonderivater
NO784211L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive acylanilid-derivater
NO784231L (no) Analogifremgangsmaate for fremstilling av fysiologisk aktive benzotiazinderivater
NO156785B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklobutan-derivater.
NO156752B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-(1-piperidinylalkyl)-4hpyrido(1,2-a)pyrimidin-4-0n derivater
NO155055C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive beta-carbolin-3-carboxylsyrederivater.
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO143219C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO150760C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotiazoler.
NO151287C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 9-hydrazono-6,7,8,9-tetrahydro-4h-pyrido(1,2-a)-pyrimidinderivater
NO156787C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater.
NO782756L (no) Fremgangsmaate for fremstilling av terapeutisk aktive antrakinonderivater
NO146865C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 16-dehydro-androstanderivater
NO155665C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,7,7a-tetrahydro-4h-thieno-(3,2-c)-pyridin-2-on-derivater.
NO148644C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive sukkerderivater.
NO159090C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater.
NO158800C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indenderivater.
NO156167C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive indolinon-derivater.
NO151660C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive imidazolderivater.
NO150158C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6,7-dimetoksyquinazolinderivater
NO164095C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive estere av 3-(3-substituerte-amino-2-hydroksypropoksy)-4-substituerte-1,2,5-tiadiazolderivater.